APG-2575 Clinical Trials
5 recruitingDrug
Phase 13Phase 23Early Phase 11
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
SLE
Ascentage Pharma Group Inc.40 enrolled1 locationNCT06182969
Recruiting
Phase 2
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Non-Hodgkins LymphomaT-Prolymphocytic Leukemia
Ascentage Pharma Group Inc.78 enrolled1 locationNCT04496349
Recruiting
Phase 1Phase 2
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ascentage Pharma Group Inc.123 enrolled18 locationsNCT04494503
Recruiting
Phase 1
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Solid TumorNeuroblastoma
Ascentage Pharma Group Inc.100 enrolled3 locationsNCT05701306
Recruiting
Early Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Hematologic Malignancies
Ascentage Pharma Group Inc.90 enrolled5 locationsNCT03537482